Vimta Labs
NSE: VIMTALABS · Healthcare Research, Analytics & Technology
Snapshot
Unlock Vimta Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vimta Labs Limited is a contract research and testing organisation providing analytical, preclinical, and clinical research services. The company serves a diverse client base across the pharmaceutical, food, healthcare, and environmental sectors.
Business Model
The company generates revenue by providing specialised laboratory testing, clinical research, and environmental assessment services to various industrial sectors on a contract basis. It leverages its technical infrastructure and regulatory expertise to support product development and compliance for its clients.
Growth Outlook
Growth is driven by the increasing demand for outsourced research and testing services within the pharmaceutical and food safety industries. The company continues to expand its service portfolio to cater to evolving regulatory standards and complex analytical requirements.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent international and domestic laboratory certifications could lead to loss of business and reputational damage.
- Client Concentration. The company's revenue may be significantly impacted by the loss of key contracts within the pharmaceutical or biopharmaceutical sectors.
- Technological Obsolescence. Rapid advancements in analytical technology require continuous capital expenditure to remain competitive in the contract research market.
- Economic Sensitivity. A slowdown in R&D spending by client industries could adversely affect the demand for contract research and testing services.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Vimta Labs and 5,000+ companies — free.
Key Metrics
REVENUE
₹407 Cr
TTM · standalone
NET PROFIT
₹78 Cr
TTM · standalone
EPS
₹17.40
TTM · standalone
RETURN ON EQUITY
19.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
24.7%
TTM · standalone
P/E
32.4x
Q4 FY26 · standalone
EV/EBITDA
16.6x
Q4 FY26 · standalone
EBITDA MARGIN
37.0%
TTM · standalone
NET PROFIT MARGIN
19.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vimta LabsVIMTALABS | 1,876 | 32.44 | 16.62 | 17.6% | 37.0% | 19.5% | 24.7% | +19.3% |
Syngene International Ltd.SYNGENE | 16,101 | 53.22 | 16.81 | 2.6% | 26.5% | 6.7% | 8.5% | -37.2% |
Indegene Ltd.INDGN | 10,574 | 30.54 | 17.38 | 23.8% | 19.7% | 14.6% | 18.4% | -12.1% |
Suven Life Sciences LimitedSUVEN | 3,433 | -27.49 | -28.43 | 6.9% | -3800.1% | -120.0% | -119.0% | +15.9% |
Fabtech Tech.FABTECH | 607 | 14.27 | 10.13 | — | 13.5% | 9.1% | 14.6% | — |
Take SolutionsTAKE | 552 | 43.59 | 40.74 | — | -27.4% | 82.3% | 51.0% | +109.3% |
As of Q4 FY26
Financials
Vimta Labs
NSE: VIMTALABS · Healthcare Research, Analytics & Technology
Snapshot
Unlock Vimta Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vimta Labs Limited is a contract research and testing organisation providing analytical, preclinical, and clinical research services. The company serves a diverse client base across the pharmaceutical, food, healthcare, and environmental sectors.
Business Model
The company generates revenue by providing specialised laboratory testing, clinical research, and environmental assessment services to various industrial sectors on a contract basis. It leverages its technical infrastructure and regulatory expertise to support product development and compliance for its clients.
Growth Outlook
Growth is driven by the increasing demand for outsourced research and testing services within the pharmaceutical and food safety industries. The company continues to expand its service portfolio to cater to evolving regulatory standards and complex analytical requirements.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent international and domestic laboratory certifications could lead to loss of business and reputational damage.
- Client Concentration. The company's revenue may be significantly impacted by the loss of key contracts within the pharmaceutical or biopharmaceutical sectors.
- Technological Obsolescence. Rapid advancements in analytical technology require continuous capital expenditure to remain competitive in the contract research market.
- Economic Sensitivity. A slowdown in R&D spending by client industries could adversely affect the demand for contract research and testing services.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Vimta Labs and 5,000+ companies — free.
Key Metrics
REVENUE
₹407 Cr
TTM · standalone
NET PROFIT
₹78 Cr
TTM · standalone
EPS
₹17.40
TTM · standalone
RETURN ON EQUITY
19.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
24.7%
TTM · standalone
P/E
32.4x
Q4 FY26 · standalone
EV/EBITDA
16.6x
Q4 FY26 · standalone
EBITDA MARGIN
37.0%
TTM · standalone
NET PROFIT MARGIN
19.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Healthcare Research, Analytics & Technology
As of Q4 FY26